Review article · 2022 · Open access

From pharmacogenetics to pharmaco-omics: Milestones and future directions

Chiara Auwerx, Marie C. Sadler, Alexandre Reymond, Zoltán Kutalik

Human Genetics and Genomics Advances, 3(2), 100100 · Published 16 March 2022 · DOI 10.1016/j.xhgg.2022.100100

Open PDFView at the publisherCite this paper

In brief

“From pharmacogenetics to pharmaco-omics: Milestones and future directions” is a 2022 review article by Chiara Auwerx and 3 co-authors, published in Human Genetics and Genomics Advances. OpenAlex counts 90 citations as of 21 November 2026. It is open access under a CC BY licence: the full text is free to read at Human Genetics and Genomics Advances.

Citations
90
Most cited in
2025 (25)
Field-weighted impact
2.14
References
264
Authors
4

Abstract

The origins of pharmacogenetics date back to the 1950s, when it was established that inter-individual differences in drug response are partially determined by genetic factors. Since then, pharmacogenetics has grown into its own field, motivated by the translation of identified gene-drug interactions into therapeutic applications. Despite numerous challenges ahead, our understanding of the human pharmacogenetic landscape has greatly improved thanks to the integration of tools originating from disciplines as diverse as biochemistry, molecular biology, statistics, and computer sciences. In this review, we discuss past, present, and future developments of pharmacogenetics methodology, focusing on three milestones: how early research established the genetic basis of drug responses, how technological progress made it possible to assess the full extent of pharmacological variants, and how multi-dimensional omics datasets can improve the identification, functional validation, and mechanistic understanding of the interplay between genes and drugs. We outline novel strategies to repurpose and integrate molecular and clinical data originating from biobanks to gain insights analogous to those obtained from randomized controlled trials. Emphasizing the importance of increased diversity, we envision future directions for the field that should pave the way to the clinical implementation of pharmacogenetics.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Auwerx, C., Sadler, M. C., Reymond, A., & Kutalik, Z. (2022). From pharmacogenetics to pharmaco-omics: Milestones and future directions. Human Genetics and Genomics Advances, 3(2), 100100. https://doi.org/10.1016/j.xhgg.2022.100100

MLA 9

Auwerx, Chiara, et al. “From pharmacogenetics to pharmaco-omics: Milestones and future directions.” Human Genetics and Genomics Advances, vol. 3, no. 2, 2022, p. 100100. https://doi.org/10.1016/j.xhgg.2022.100100.

Chicago

Auwerx, Chiara, Marie C. Sadler, Alexandre Reymond, and Zoltán Kutalik. 2022. “From pharmacogenetics to pharmaco-omics: Milestones and future directions.” Human Genetics and Genomics Advances 3 (2): 100100. https://doi.org/10.1016/j.xhgg.2022.100100.

Harvard

Auwerx, C. et al. (2022) ‘From pharmacogenetics to pharmaco-omics: Milestones and future directions’, Human Genetics and Genomics Advances, 3(2), p. 100100. doi:10.1016/j.xhgg.2022.100100.

IEEE

C. Auwerx, M. C. Sadler, A. Reymond, and Z. Kutalik, “From pharmacogenetics to pharmaco-omics: Milestones and future directions,” Human Genetics and Genomics Advances, vol. 3, no. 2, p. 100100, 2022, doi: 10.1016/j.xhgg.2022.100100.

BibTeX

@article{auwerx2022from,
  title     = {{From pharmacogenetics to pharmaco-omics: Milestones and future directions}},
  author    = {Auwerx, Chiara and Sadler, Marie C. and Reymond, Alexandre and Kutalik, Zoltán},
  journal   = {Human Genetics and Genomics Advances},
  year      = {2022},
  volume    = {3},
  number    = {2},
  pages     = {100100},
  doi       = {10.1016/j.xhgg.2022.100100},
  url       = {https://doi.org/10.1016/j.xhgg.2022.100100}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202111
202288
20231414
20242121
20252525
20262121

Its field-weighted citation impact is 2.14: it has been cited 2.14 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism

  • pharmacogenetics
  • drug-gene interactions
  • multi-omics integration
  • drug repurposing
  • population diversity

Work with this paper

Most-cited papers in Pharmacology, Toxicology and Pharmaceutics

All highly cited Pharmacology, Toxicology and Pharmaceutics papers

Questions about this paper

How do I cite this paper in APA style?

Auwerx, C., Sadler, M. C., Reymond, A., & Kutalik, Z. (2022). From pharmacogenetics to pharmaco-omics: Milestones and future directions. Human Genetics and Genomics Advances, 3(2), 100100. https://doi.org/10.1016/j.xhgg.2022.100100

How many times has this paper been cited?

90 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Human Genetics and Genomics Advances: sign in and open the PDF from this page.

Who wrote this paper?

Chiara Auwerx, Marie C. Sadler, Alexandre Reymond, Zoltán Kutalik.

What is the DOI of this paper?

10.1016/j.xhgg.2022.100100, permanently at https://doi.org/10.1016/j.xhgg.2022.100100. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.